UNIVERSITY OF DUNDEE AND CORBIN THERAPEUTICS ENTER INTO COLLABORATION AGREEMENT TO DISCOVER NOVEL UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

Dundee, Scotland UK and Montreal, Québec, Canada, May 22, 2017 – University of Dundee, its Drug Discovery Unit (“DDU”), and Corbin Therapeutics (“Corbin”) are pleased to announce their collaboration agreement to screen and identify small molecules capable of efficiently inhibiting a well-conserved ubiquitin-specific protease, USP15. Corbin focuses on a novel therapeutic approach to treat various Read more about UNIVERSITY OF DUNDEE AND CORBIN THERAPEUTICS ENTER INTO COLLABORATION AGREEMENT TO DISCOVER NOVEL UBIQUITIN-SPECIFIC PROTEASE INHIBITORS[…]

CORBIN THERAPEUTICS AND PROTEOREX THERAPEUTICS ANNOUNCE A RESEARCH AND DEVELOPMENT COLLABORATION TO DISCOVER NOVEL UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

Toronto, ON, and Montreal, QC, May 19, 2017 – Proteorex Therapeutics Inc. (“Proteorex”), headquartered in JLABS @ Toronto, is excited to announce the start of their research and development collaboration with Montreal-based Corbin Therapeutics Inc. (“Corbin”). The collaboration will identify small molecules which efficiently inhibit an important and highly conserved ubiquitin protein. Proteorex will receive Read more about CORBIN THERAPEUTICS AND PROTEOREX THERAPEUTICS ANNOUNCE A RESEARCH AND DEVELOPMENT COLLABORATION TO DISCOVER NOVEL UBIQUITIN-SPECIFIC PROTEASE INHIBITORS[…]

AMORCHEM SPINS OUT ITS USP15-DEUBIQUITINYLATION (DUB) DRUG DISCOVERY PLATFORM INTO CORBIN THERAPEUTICS, WITH A FIRST 1M$ SEED INVESTMENT

Montreal, Quebec – January 9, 2017 – AmorChem is pleased to announce the creation of Corbin Therapeutics, its third spin-off company focusing on a novel therapeutic approach to treat various inflammation-based diseases via inhibition of the ubiquitin carboxyl-terminal hydrolase 15 (USP15) enzyme. All rights to the USP15 technology initially held by AmorChem have been transferred Read more about AMORCHEM SPINS OUT ITS USP15-DEUBIQUITINYLATION (DUB) DRUG DISCOVERY PLATFORM INTO CORBIN THERAPEUTICS, WITH A FIRST 1M$ SEED INVESTMENT[…]